EU share of China's rare earth magnet shipments jumps in June
rebounded in June – and the proportion of its permanent magnets sent to the European Union rose to its highest level this year.
Last month, China exported 3,188 tonnes of rare earth permanent magnets – an essential component for a variety of products, including electric vehicles (EVs), wind turbines, smartphones and aerospace vessels. This represented a 157.5 per cent increase from May and a 38.2 per cent drop year on year, according to customs data.
Of this sum, some 1,364 tonnes of magnets were shipped to the EU, accounting for 43 per cent of June exports, up from 32 per cent in May. By comparison, the proportion for the United States stood at 11 per cent in June and 4 per cent in May.
The US bought 353 tonnes of the magnets in June, a 660 per cent surge over the figure for May, though still down 52 per cent from the year before.
After China imposed
export controls on seven rare earth elements and magnets in retaliation for US tariff hikes in April, companies were required to obtain a government permit before shipping these products overseas.
As a result, China's rare earth magnet export volume plummeted in April and May, each dropping by around 50 per cent month to month.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
South China Morning Post
2 hours ago
- South China Morning Post
Pfizer, Chinese biotech firm 3SBio complete worldwide licensing deal for cancer drug
First announced in May, the deal will see 3SBio – based in Shenyang, capital of northeastern Liaoning province – receive a US$1.25 billion upfront payment from Pfizer for the exclusive right to sell its cancer drug, SSGJ-707, outside China. Under the terms of their agreement, Pfizer will also pay 3SBio up to US$150 million to solely develop and commercialise SSGJ-707 within the mainland, the two companies said on Thursday. Pfizer also agreed to buy 31.1 million new shares in S3Bio, or a 1.3 per cent equity stake, for HK$785 million, according to a stock exchange filing. The deal at HK$25.2055 per share represents a 17 per cent discount to its market price on Thursday. 3SBio's shares fell 6.41 per cent to HK$28.45 on Friday. The transaction reflected the strong momentum of Chinese biotech firms in the field of drugs research and the increased interest from major foreign pharmaceutical companies to license their intellectual property.
AllAfrica
2 hours ago
- AllAfrica
Weak hands at the helm, from Tokyo to Kiev
Subscribe now with a one-month trial for only $1, then enjoy the first year at an exclusive rate of just $99. Japanese politics enters uncharted territory Scott Foster reports on the crushing electoral defeat for Japan's ruling LDP-led coalition in recent Upper House elections. Voter dissatisfaction with inflation, taxes, and immigration fueled a sharp rise for populist challengers, signaling a shift in Japan's political landscape. From Brussels to Berlin, Trump sees an EU ripe to squeeze Diego Faßnacht argues that Germany's much-publicized €631 billion corporate investment pledge is more political theater than economic transformation. Washington, meanwhile, plans sweeping tariffs on European imports, confident that Germany will bear the brunt. Low expectations in Istanbul as Ukraine war grinds on James Davis observes that talks between Russia and Ukraine in Istanbul yielded little optimism, while Zelensky's controversial move to bring Ukraine's anti-corruption agency under presidential control has sparked protests and speculation about his political future.
South China Morning Post
2 hours ago
- South China Morning Post
Hong Kong life insurance sales jump 43% to record high in first quarter
Life insurance sales in Hong Kong rose 43 per cent in the first quarter to a record high on demand for protection and estate planning from high-net-worth customers and visitors from mainland China, as the city seeks to become a wealth management hub to rival global leaders like Switzerland. The industry wrote HK$93.4 billion (US$12 billion) worth of new life policies in the first quarter, up from HK$65.3 billion a year earlier, the Insurance Authority said on Friday. It was the highest first-quarter sales tally since the authority was established in 2016. Hong Kong had a record year in 2024, when insurers posted a 21.4 per cent jump in sales to HK$219.8 billion, courtesy of a world-record policy sold by HSBC Life. 'Hong Kong's insurance industry continued its strong momentum in early 2025, supported by sustained demand for savings, health, and protection products from both local customers and mainland Chinese visitors,' said Patrick Graham, CEO of Manulife Hong Kong and Macau. The regulator did not disclose policy sales to mainland visitors, having earlier decided to release such statistics after a review about the disclosures of non-local buyers.
